Free Trial

Acumen Pharmaceuticals (ABOS) Competitors

Acumen Pharmaceuticals logo
$1.56 -0.12 (-6.85%)
As of 12:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABOS vs. ARCT, BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, and AMRN

Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Arcturus Therapeutics (ARCT), Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

Acumen Pharmaceuticals vs. Its Competitors

Acumen Pharmaceuticals (NASDAQ:ABOS) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Acumen Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Arcturus Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acumen PharmaceuticalsN/AN/A-$102.33M-$1.94-0.81
Arcturus Therapeutics$131.27M3.07-$80.94M-$2.53-5.88

Acumen Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Acumen Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Acumen PharmaceuticalsN/A -58.24% -46.53%
Arcturus Therapeutics -47.47%-27.41%-19.01%

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 9.3% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus price target of $6.33, indicating a potential upside of 304.69%. Arcturus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 263.24%. Given Acumen Pharmaceuticals' higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 1 mentions for Arcturus Therapeutics and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.00 equaled Arcturus Therapeutics'average media sentiment score.

Company Overall Sentiment
Acumen Pharmaceuticals Neutral
Arcturus Therapeutics Neutral

Summary

Arcturus Therapeutics beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABOS vs. The Competition

MetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$94.19M$3.06B$5.68B$9.50B
Dividend YieldN/A2.44%4.05%3.99%
P/E Ratio-0.8020.9727.9520.00
Price / SalesN/A250.27397.1083.19
Price / CashN/A41.9636.1958.45
Price / Book0.528.288.665.83
Net Income-$102.33M-$55.19M$3.24B$258.39M
7 Day Performance5.74%5.06%3.33%2.30%
1 Month Performance24.21%17.64%10.84%12.42%
1 Year Performance-51.40%7.00%35.32%21.16%

Acumen Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABOS
Acumen Pharmaceuticals
2.3491 of 5 stars
$1.57
-6.8%
$6.33
+304.7%
-52.5%$94.19MN/A-0.8020
ARCT
Arcturus Therapeutics
1.7983 of 5 stars
$13.31
-3.4%
$54.00
+305.7%
-34.6%$360.98M$131.27M-5.26180
BNTC
Benitec Biopharma
1.6721 of 5 stars
$13.25
+3.7%
$23.83
+79.9%
+31.8%$347.81M$80K-8.7720
GOSS
Gossamer Bio
3.5433 of 5 stars
$1.53
+12.5%
$8.25
+439.2%
+74.8%$347.77M$114.70M-6.65180High Trading Volume
CMPS
COMPASS Pathways
1.9847 of 5 stars
$3.71
+1.1%
$17.00
+358.2%
-36.5%$347.11MN/A-1.86120Upcoming Earnings
PRTA
Prothena
3.9499 of 5 stars
$6.43
+0.5%
$31.50
+389.9%
-72.2%$346.11M$137.94M-3.09130News Coverage
ALT
Altimmune
2.0057 of 5 stars
$4.26
+2.9%
$18.20
+327.2%
-33.3%$345.53M$20K-3.3850
AURA
Aura Biosciences
2.7151 of 5 stars
$6.75
+5.5%
$22.00
+225.9%
-25.8%$339.32MN/A-3.5550Positive News
RNAC
Cartesian Therapeutics
1.6985 of 5 stars
$13.06
-2.0%
$40.00
+206.3%
-21.3%$338.91M$38.91M-0.2564News Coverage
CAPR
Capricor Therapeutics
2.6432 of 5 stars
$7.39
-3.3%
$22.56
+205.2%
+42.7%$337.58M$22.27M-5.20101
AMRN
Amarin
0.3072 of 5 stars
$16.10
-4.9%
$12.00
-25.5%
-0.7%$333.43M$228.61M-4.42360Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners